Ho brings to Beam more than 15 years of life sciences experience as a clinical neurologist, neuroscientist and leader in biopharmaceutical drug development.
Prior to her current role as founding chief medical officer and head of development at Denali Therapeutics, Dr. Ho served as vice president of Early Clinical Development at Genentech.
In that role, she was responsible for delivery of pivotal trial-ready drug candidates to the Roche / Genentech late-stage development groups in neurology, ophthalmology, immunology and infectious disease.
During her eight-year tenure at Genentech, she held positions of increasing responsibility across both the early and late stage clinical development groups with development oversight for multiple therapeutic areas and molecules including crenezumab for Alzheimer's disease, lampalizumab for dry age related macular degeneration, and development activities leading to the approvals of ocrelizumab for multiple sclerosis and Rituxan for Wegener's granulomatosis and microscopic polyangiitis.
Prior to Genentech, Ho was on faculty in the Department of Neurology at Stanford University and subsequently a Medical director at Johnson and Johnson.
Ho received her undergraduate degree in biochemical sciences from Harvard College and her M.D. from Cornell University. She completed her medical internship and neurology residency at Harvard and served as Chief Resident of Neurology at the Massachusetts General Hospital / Brigham and Women's Hospital.
Beam Therapeutics is developing precision genetic medicines through base editing.
Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
Headquartered in Cambridge, Massachusetts, the company is backed by F-Prime Capital Partners and ARCH Venture Partners, two of the world's leading biotech venture capital firms.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial